FDA Approves Ilumya for Adults With Active Psoriatic Arthritis

Sun Pharma's interleukin-23 (IL-23) inhibitor, Ilumya (tildrakizumab-asmn), has received FDA approval for adults with active psoriatic arthritis. This decision expands the drug's indication from plaque psoriasis into rheumatology, offering a new treatment option for an estimated 2.4 million Americans affected by the disease.